Innovative Product Launches Sino Biological regularly introduces high-quality, specialized reagents such as high-purity Nipah virus proteins and recombinant E1 and E2 proteins to support urgent research needs, indicating strong demand for cutting-edge bioproducts in emerging infectious disease research.

Strategic Expansions The company's recent partnership extension with BioGeometry and the launch of flagship products like ProPure suggest ongoing expansion opportunities, particularly in digital biology and endotoxin-free protein segments, appealing to clients seeking comprehensive, innovative solutions.

Award Recognition Winning industry awards such as the Supplier Recognition Award and the drug discovery services accolade highlights Sino Biological’s reputation for quality and reliability, making it an attractive partner for organizations prioritizing high standards and trusted collaborations.

Market Leadership As a global leader in recombinant protein and antibody production with facilities in North America and strong ties to academic and industrial sectors, Sino Biological presents a substantial opportunity to target biotech firms, research labs, and pharma companies investing in immunoassays and vaccine development.

Growth and Revenue With annual revenues ranging from 50 to 100 million dollars and a focus on innovative biotechnologies, Sino Biological offers substantial sales potential in reagents, assay kits, and custom CRO services, particularly as biotech R&D investment continues to grow globally.